CD8A and neoplasm: Similarly, a genetically modified oncolytic Ad, H101, shows promising results when combined with anti-PD-1 antibodies in a mouse model of CRC, leading to reduced tumor volume, increased infiltration of CD8+ T cells, and enhanced anti-tumor immune response.165